title: In vitro production of TNF-alpha, IL-1 beta and IL-6 by mononuclear blood cells of patients with renal cell carcinoma undergoing rIL-2 treatment. Relation between clinical response and TNF-alpha production.
abstract: The purpose of this study was to examine the production of IL-1 beta, IL-6 and TNF-alpha by peripheral blood mononuclear cells in patients with renal cell carcinoma treated with recombinant interleukin 2 (rIL-2). Peripheral blood mononuclear cells (PBMC) were purified from blood samples obtained six times during therapy and the production of IL-1 beta, IL-6 and TNF-alpha were determined after 18 h culture of the PBMC in culture medium or in medium containing 10 micrograms lipopolysaccharide (LPS)/ml, 10 ng LPS/ml or 1000 units rIL-2/ml. In vivo therapy with rIL-2 resulted in substantial changes in the production of the three cytokines. Only the production of TNF-alpha following in vitro stimulation with rIL-2 was related to the clinical response, being significant lower in responding patients than in non-responders (P less than 0.05). These findings suggest that the rIL-2-induced TNF-alpha production of PBMC in vitro is lower in renal cancer patients that respond to rIL-2 therapy than in non-responding patients.
authors.affiliation: Department of Tumor Cell Biology, Fibiger Institute, Danish Cancer Society, Copenhagen.
authors.forename: G G
authors.initials: GG
authors.lastname: Hermann
authors.forename: J
authors.initials: J
authors.lastname: Zeuthan
authors.forename: P F
authors.initials: PF
authors.lastname: Geertsen
authors.forename: M H
authors.initials: MH
authors.lastname: Claesson
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000097:blood; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000097:blood; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha